ASH 2019 – Multiple Myeloma: Wrap-Up

Patients with “challenging-to-treat” relapsed multiple myeloma showed promising responses to a new 4-drug combination, one of the first of its kind to be used in multiple myeloma. Read More ›

Now that patients with multiple myeloma are living longer, researchers are focusing more on patients’ quality of life during and after cancer treatment. New research says there’s good news: 1 study found that adding an extra drug to a standard treatment made patients live longer, with no negative impact on their quality of life. Read More ›

CAR T-cell therapy – a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells – could soon be used to fight multiple myeloma. CAR T-cell therapy has shown huge promise in other types of cancer but would be a new treatment for patients with this type of cancer. Read More ›

Exciting new research shows that adding daratumumab to a common multiple myeloma treatment slowed down cancer progression in patients who had relapsed or did not respond to other treatments. Read More ›

In patients with newly diagnosed multiple myeloma who were fit for transplant, adding daratumumab to a commonly used treatment regimen led to impressive responses. Read More ›

Exciting research from the annual ASH conference showed that a new drug combination led to significant improvements in patients with systemic amyloid light chain amyloidosis. This could mean more treatment options for patients with a very limited choice of therapies. Read More ›

When given daratumumab along with standard-of-care treatment, patients with newly diagnosed, transplant-ineligible multiple myeloma lived longer than those who received standard of care alone. Read More ›

CAR T-cell therapy, a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells, has led to exciting results in other types of cancer…could it soon be used to treat multiple myeloma? Read More ›

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice

Learn more about our family of publications.

View Our Publications